IRVINE, Calif., Oct. 19 /PRNewswire/ -- Xytis Inc., a privately held biotechnology company focused on developing novel therapeutics to treat central nervous system (CNS) diseases, today announced that Gordon H. Busenbark has joined the company as Chief Financial Officer. Mr.

IRVINE, Calif. and NYON, Switzerland, March 13 /PRNewswire/ -- Xytis announced it has enrolled the first patient in the Company's Phase II clinical trial with Anatibant for the treatment of traumatic brain injury (TBI).

IRVINE, Calif., and NYON, Switzerland, Jan. 9 /PR

IRVINE, Calif. and NYON, Switzerland, Jan. 8 /PRN

Xytis Inc. ("Xytis") announced today that it has r